Medical gadget maker Medtronic Plc (NYSE: MDT) on Tuesday reported stronger-than-expected adjusted earnings for the third quarter of fiscal 2026. The administration reaffirmed its full-year 2026 steering.
Third-quarter earnings, excluding one-off objects, declined to $1.36 per share from $1.39 per share within the year-ago quarter, however got here in above estimates. On an unadjusted foundation, web revenue was $1.14 billion or $0.89 per share in Q3, versus $1.29 billion or $1.01 per share in Q3 2025.
Complete revenues grew 8.7% year-over-year to $9.0 billion through the three months, according to estimates. Revenues of the Cardiovascular and Neuroscience segments elevated by 13.8% and 4.1% respectively.
Thierry Piéton, Medtronic’s CEO, stated, “ We continued to invest in R&D to strengthen our innovation pipeline, funded significant growth opportunities while driving G&A leverage, and we executed on our M&A and venture strategy with two key transactions in the quarter. Bottom line, we are executing on our roadmap and positioning the business for sustainable growth.”
Administration reaffirmed its FY26 natural income development forecast of 5.5% and adjusted earnings per share steering of $5.62 to $5.66. Excluding the potential impression from tariffs, the steering represents FY26 earnings per share development of roughly 4.5%.
